146 related articles for article (PubMed ID: 34605009)
1. Clinical and Molecular Perspectives on Inflammation-Mediated Regulation of Drug Metabolism and Transport.
Dunvald AD; Järvinen E; Mortensen C; Stage TB
Clin Pharmacol Ther; 2022 Aug; 112(2):277-290. PubMed ID: 34605009
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic, Functional, and Clinical Aspects of Pro-inflammatory Cytokine Mediated Regulation of ADME Gene Expression in 3D Human Liver Spheroids.
Klöditz K; Tewolde E; Nordling Å; Ingelman-Sundberg M
Clin Pharmacol Ther; 2023 Sep; 114(3):673-685. PubMed ID: 37307233
[TBL] [Abstract][Full Text] [Related]
3. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation.
Kugler N; Klein K; Zanger UM
Biochem Pharmacol; 2020 Jan; 171():113725. PubMed ID: 31758923
[TBL] [Abstract][Full Text] [Related]
4. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
5. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
8. The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions.
Gatti M; Pea F
Clin Pharmacokinet; 2022 Nov; 61(11):1519-1544. PubMed ID: 36059001
[TBL] [Abstract][Full Text] [Related]
9. Role of Adaptor Protein Toll-Like Interleukin Domain Containing Adaptor Inducing Interferon β in Toll-Like Receptor 3- and 4-Mediated Regulation of Hepatic Drug Metabolizing Enzyme and Transporter Genes.
Shah P; Omoluabi O; Moorthy B; Ghose R
Drug Metab Dispos; 2016 Jan; 44(1):61-7. PubMed ID: 26470915
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters.
Nguyen TV; Ukairo O; Khetani SR; McVay M; Kanchagar C; Seghezzi W; Ayanoglu G; Irrechukwu O; Evers R
Drug Metab Dispos; 2015 May; 43(5):774-85. PubMed ID: 25739975
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
13. Inflammation Suppresses Patients' Ability to Metabolize Cytochrome P450 Substrate Drugs.
White CM
Ann Pharmacother; 2022 Jul; 56(7):809-819. PubMed ID: 34590872
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
Utkarsh D; Loretz C; Li AP
Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
[TBL] [Abstract][Full Text] [Related]
15. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.
Polasek TM; Elliot DJ; Somogyi AA; Gillam EM; Lewis BC; Miners JO
Br J Clin Pharmacol; 2006 May; 61(5):570-84. PubMed ID: 16669850
[TBL] [Abstract][Full Text] [Related]
17. Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
de Vries EM; Lammers LA; Achterbergh R; Klümpen HJ; Mathot RA; Boelen A; Romijn JA
PLoS One; 2016; 11(7):e0159552. PubMed ID: 27434302
[TBL] [Abstract][Full Text] [Related]
18. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
19. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
de Jong LM; Jiskoot W; Swen JJ; Manson ML
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 in Pharmacogenetics: An Update.
Tornio A; Backman JT
Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
